Literature DB >> 12069991

GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.

Jeffrey E Edwards1, Kenneth R Brouwer, Patrick J McNamara.   

Abstract

The goal of this study was to determine the distribution of unbound amprenavir in the central nervous system (CNS) of rats. The concentration of unbound amprenavir in the extracellular fluid of the brain and the blood was examined in the presence and absence of the MDR modulator GF120918 by microdialysis. The brain-to-blood ratio of amprenavir in the absence and presence of GF120918 was found to be significantly different (P < 0.003; 0.076 and 0.617, respectively). The use of the MDR modulator GF120918 could potentially increase the penetration of human immunodeficiency virus protease inhibitors into the CNS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069991      PMCID: PMC127290          DOI: 10.1128/AAC.46.7.2284-2286.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

Authors:  E F Choo; B Leake; C Wandel; H Imamura; A J Wood; G R Wilkinson; R B Kim
Journal:  Drug Metab Dispos       Date:  2000-06       Impact factor: 3.922

2.  Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis.

Authors:  D E Burgio; M P Gosland; P J McNamara
Journal:  Biochem Pharmacol       Date:  1996-04-12       Impact factor: 5.858

Review 3.  Application of microdialysis in pharmacokinetic studies.

Authors:  W F Elmquist; R J Sawchuk
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

4.  Effect of the p-glycoprotein inhibitor, cyclosporin A, on the distribution of rhodamine-123 to the brain: an in vivo microdialysis study in freely moving rats.

Authors:  Q Wang; H Yang; D W Miller; W F Elmquist
Journal:  Biochem Biophys Res Commun       Date:  1995-06-26       Impact factor: 3.575

5.  Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.

Authors:  D J Livington; S Pazhanisamy; D J Porter; J A Partaledis; R D Tung; G R Painter
Journal:  J Infect Dis       Date:  1995-11       Impact factor: 5.226

Review 6.  P-glycoproteins and multidrug resistance.

Authors:  W T Bellamy
Journal:  Annu Rev Pharmacol Toxicol       Date:  1996       Impact factor: 13.820

7.  Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.

Authors:  Z Yang; R C Brundage; R H Barbhaiya; R J Sawchuk
Journal:  Pharm Res       Date:  1997-07       Impact factor: 4.200

8.  Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

Authors:  J W Polli; J L Jarrett; S D Studenberg; J E Humphreys; S W Dennis; K R Brouwer; J L Woolley
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

9.  4-Trimethylammonium antipyrine: a quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis.

Authors:  D D Allen; P A Crooks; R A Yokel
Journal:  J Pharmacol Toxicol Methods       Date:  1992-11       Impact factor: 1.950

10.  Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion.

Authors:  Y Wang; R J Sawchuk
Journal:  J Pharm Sci       Date:  1995-07       Impact factor: 3.534

View more
  22 in total

Review 1.  P glycoprotein in human immunodeficiency virus type 1 infection and therapy.

Authors:  Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

Review 2.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

3.  Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats.

Authors:  Ritesh Jain; Sridhar Duvvuri; Viral Kansara; Nanda Kishore Mandava; Ashim K Mitra
Journal:  Int J Pharm       Date:  2006-12-03       Impact factor: 5.875

4.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

Review 5.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

6.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

7.  Assessment and modulation of phillyrin absorption by P-gp using Caco-2 cells and MDR1-MDCKII cells.

Authors:  Yun-Xia Li; Liang-Hong Ye; Xue-Hua Jiang; Cheng Peng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-02-20       Impact factor: 2.441

Review 8.  Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies.

Authors:  Ranjeet Prasad Dash; R Jayachandra Babu; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-12       Impact factor: 2.441

9.  Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.

Authors:  Corbin J Bachmeier; Timothy J Spitzenberger; William F Elmquist; Donald W Miller
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

Authors:  Ramola Sane; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharm Sci       Date:  2013-01-18       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.